Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3 (Targeted Oncology, (2020), 15, 4, (467-475), 10.1007/s11523-020-00742-w)

Diana Lüftner; Gary H. Lyman; João Gonçalves; Xavier Pivot; Minji Seo

ArticleOPEN ACCESS

Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3 (Targeted Oncology, (2020), 15, 4, (467-475), 10.1007/s11523-020-00742-w)

Targeted Oncology

DOI: 10.1007/s11523-020-00761-7

1Citations

6Readers

Abstract

The article Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.

Cite

CITATION STYLE

APA

Lüftner, D., Lyman, G. H., Gonçalves, J., Pivot, X., & Seo, M. (2020, December 1). Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3 (Targeted Oncology, (2020), 15, 4, (467-475), 10.1007/s11523-020-00742-w). Targeted Oncology. Adis. https://doi.org/10.1007/s11523-020-00761-7

Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3 (Targeted Oncology, (2020), 15, 4, (467-475), 10.1007/s11523-020-00742-w)

Abstract

Cite

Register to see more suggestions